CLINICAL TRIALS PROFILE FOR INCOBOTULINUMTOXINA

All Clinical Trials for incobotulinumtoxina

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00406367 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-10-01	Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.
NCT00407030 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-07-01	At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxinA (Xeomin) during the extension period.
NCT00430963 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-10-01	IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study investigated the efficacy and safety of IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo. The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days each.
NCT00432666 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-06-01	IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin. Injected into the muscle, incobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for treatment of various neurological conditions. This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of post-stroke spasticity of the upper limb.
NCT00465738 ↗	IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity	Completed	Merz Pharmaceuticals GmbH	Phase 3	2007-02-01	This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of arm tightness (upper limb spasticity) using two different dilutions of incobotulinumtoxinA (Xeomin).
NCT00507637 ↗	Blepharospasm Short Interval	Terminated	Merz Pharmaceuticals GmbH	Phase 2	2007-08-01	The objective of this Phase II study is to show that pre-treated patients with BEB with the need of shortened injection intervals achieve an improved and stable quality of life level if they receive repeated NT 201 injections at short injection intervals. In addition, the tolerability of repeated shortened NT 201 administrations in patients with BEB including the development of neutralizing antibodies will be investigated.
NCT00512135 ↗	Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines	Completed	Merz Pharmaceuticals GmbH	Phase 3	2007-06-18	The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ 60201-0741/1 were eligible to participate in this repeat-dose study.

Clinical Trial Conditions for incobotulinumtoxina

Condition Name

Condition Name for incobotulinumtoxina
Intervention	Trials
Glabellar Frown Lines	4
Moderate to Severe Glabellar Frown Lines	3
Cerebral Palsy	3
Stroke	2

Condition MeSH

Condition MeSH for incobotulinumtoxina
Intervention	Trials
Muscle Spasticity	10
Cerebral Palsy	6
Tremor	5
Paralysis	4

Clinical Trial Locations for incobotulinumtoxina

Trials by Country

Trials by Country for incobotulinumtoxina
Location	Trials
United States	82
Germany	14
Canada	13
France	5
Spain	5

Trials by US State

Trials by US State for incobotulinumtoxina
Location	Trials
New York	8
Florida	8
Tennessee	7
California	7
North Carolina	5

Clinical Trial Progress for incobotulinumtoxina

Clinical Trial Phase

Clinical Trial Phase for incobotulinumtoxina
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	19
Phase 2	21

Clinical Trial Status

Clinical Trial Status for incobotulinumtoxina
Clinical Trial Phase	Trials
Completed	25
Not yet recruiting	12
Recruiting	7

Clinical Trial Sponsors for incobotulinumtoxina

Sponsor Name

Sponsor Name for incobotulinumtoxina
Sponsor	Trials
Merz Pharmaceuticals GmbH	27
Merz North America, Inc.	6
Merz Pharmaceuticals, LLC	4

Sponsor Type

Sponsor Type for incobotulinumtoxina
Sponsor	Trials
Industry	39
Other	28
U.S. Fed	2